Free Trial
NASDAQ:EQ

Equillium Q2 2025 Earnings Report

Equillium logo
$1.90 +0.34 (+21.79%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.97 +0.07 (+3.74%)
As of 08/22/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Equillium EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.14
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Equillium Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Equillium Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 13, 2025
Conference Call Time
6:00PM ET

Earnings Documents

Equillium Earnings Headlines

Financial Review: Equillium (NASDAQ:EQ) and Imunon (NASDAQ:IMNN)
This stock could leave NVDA in the dust
Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.tc pixel
Equillium (EQ) to Release Earnings on Thursday
Equillium Secures $30 Million in Private Placement
See More Equillium Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Equillium? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Equillium and other key companies, straight to your email.

About Equillium

Equillium (NASDAQ:EQ), a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

View Equillium Profile

More Earnings Resources from MarketBeat